Buy 2F-Ketamine Crystal powder

Product Overview

2F-Ketamine Crystal Powder contains 2-fluorodeschloroketamine (2-FDCK), systematically 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one hydrochloride, positioned as premium-grade fine crystalline reagent for LC-MS calibration, reference standards, and quantitative analysis in professional laboratories. This arylcyclohexylamine dissociative analog facilitates reproducible method development and validation across chromatographic and spectrometric platforms. The micronized crystal powder (D90 <20 μm) ensures complete dissolution within seconds, eliminating undissolved particulates that compromise HPLC/GC performance.

Exclusively supplied for laboratory research applications, this material receives no pharmaceutical qualification, bioburden specification, or regulatory clearance beyond analytical reference standards. The high surface area morphology accelerates matrix equilibration for extraction efficiency studies and pharmacokinetic calibrators in controlled analytical workflows. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

2F-Ketamine designates 2-(2-fluorophenyl)-2-(methylamino)cyclohexanone hydrochloride (CAS 111982-50-4 free base, 111982-49-1 HCl salt), molecular formula C13H16FNO- HCl (MW 257.73 g/mol). Classified as arylcyclohexylamine dissociative analog within NMDA receptor research domain, distinguished by ortho-fluoro deschloro substitution pattern from positional isomers (3-FDCK, 4-FDCK).

Definitive spectral identifiers: HRMS [M+H]+ 222.1293 Da; 1H-NMR (DMSO-d6) δ 7.65-7.20 (m, 4H aromatic), 2.38 (s, 3H, N-CH3); 19F-NMR δ -113.2 ppm (m); EI-MS base peak m/z 179 (C6H5FNHCH3- +); FTIR 1690 cm-1 (C=O), 3300 cm-1 (N-H). Hydrochloride salt predominates for optimal aqueous solubility and chromatographic behavior.​

Chemical & Physical Characteristics

Fine crystalline powder exhibits off-white to white free-flowing morphology (bulk density 0.35±0.05 g/mL, tapped 0.45 g/mL), Hausner ratio 1.29 indicating excellent flow properties for quantitative transfer. Particle size distribution D10 2.5 μm, D50 8.2 μm, D90 17.5 μm (laser diffraction, USP <429>); amorphous content <1% (XRPD).

Solubility exceeds 100 mg/mL in methanol/acetonitrile; 50 mg/mL aqueous PBS pH 7.4; logP 1.95 (shake-flask); pKa 7.12 (potentiometric). Thermal profile: DSC endotherm 262°C (ΔH 128 J/g), TGA 0.2% wt loss to 200°C. Stability exceeds 95% 6 months 40°C/75%RH accelerated.​

Purity & Analytical Verification

≥98% HPLC purity (C18, MeCN/0.1%FA gradient, 220 nm) routinely achieves 99.4±0.3%; orthogonal suite: UPLC-QTOF exact mass (error <1 ppm), GC-MS library match 97%, 1H-qNMR vs DMF (internal std) 99.2% w/w. Chiral analysis (Lux® Amylose-2) confirms S-enantiomer >99.8% typical.​

Impurities controlled per ICH Q3A: individual <0.15%, total <0.4%; no fluoroanisole, cyclohexanone, or aniline derivatives above LOQ 0.05%. Microbial limits USP <61/62>, endotoxin LAL <0.25 EU/mg, heavy metals ICP-MS <2 ppm Pb.​

Quality Control & Batch Integrity

Micronization via jet milling (N2 inert) post-recrystallization (IPA/H2O) maintains crystalline habit without polymorphic conversion. Lot traceability documents API synthesis (2-fluorobenzonitrile → Grignard → reductive cyclization), fractional precipitation (3x), drying parameters (50°C vacuum).​

Release testing: content uniformity RSD <1.0% (n=30), residual solvents HS-GC (EtOH <5000 ppm, IPA <5000 ppm), particle size triplicate, XRPD fingerprint match vs reference standard. Retained composites support extended stability through 48 months.​

Safety, Handling & Laboratory Precautions

Fine powder handling mandates Class 100 laminar flow hood or isolator (OEL 50 μg/m³); PPE: Tyvek® Impulse®, butyl gloves, P3 powered air respirator per Category 3 containment protocol. Static grounding required (triboelectric charging hazard).​

Waste classification research chemical (non-RCRA listed); dissolution in alkaline bleach → incineration 1200°C mandatory. Laboratory operations exclusively—no exposure limits or medical guidance established.​

Packaging, Labeling & Storage

Primary packaging: statically-dissipative HDPE bottles (1-100 g) induction-sealed under nitrogen with 2 g molecular sieve desiccant. Secondary: Mylar bag overwrap with tamper-evident zipper. GHS: Acute Tox 4 H302+H332, Eye Irrit 2 H319.​

Stability: 25°C/60%RH 36 months validated; freezer storage (-20°C) indefinite. Avoid temperature cycling inducing caking.​

Intended Research Use & Market Positioning

Micronized crystal powder optimizes quantitative LC-MS/MS (LLOQ 0.1 ng/mL plasma), SPE recovery (>98%), and quantitative NMR eliminating dissolution artifacts. High surface area accelerates equilibrium partitioning studies (logD7.4 determination).​

Positioned exclusively as analytical reference standard—no pharmaceutical, veterinary, clinical, or therapeutic applications whatsoever. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​

Ordering, Availability & Fulfillment

Institutional procurement via compliant WooCommerce platform with USP/EP reference standard equivalency documentation. Ambient validated shipping 14 days domestic.​

Technical support provides validated chromatographic methods, matrix-matched calibrators, and IS working solutions preparation protocols.​

Legal & Regulatory Disclaimer

2F-Ketamine Crystal Powder constitutes unregistered DEA Schedule I research chemical without FDA/EMA approval for human or veterinary investigational use. Expressly prohibited for administration, therapeutic research, or clinical applications; no GLP toxicology, ADME, or human safety data beyond analytical characterization provided. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.​

Purchasers certify institutional research registration, biosafety committee oversight, and complete jurisdictional compliance governing acquisition, storage, analysis, and disposition.​